We are live on ! Find out more
KLRS

Kalaris Therapeutics
KLRS

90 hedge funds and large institutions have $115M invested in Kalaris Therapeutics in 2023 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 40 increasing their positions, 20 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 20

0.02% less ownership

Funds ownership: 2.07% → 2.05% (-0.02%)

4% less funds holding

Funds holding: 94 → 90 (-4)

22% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 18

37% less capital invested

Capital invested by funds: $184M → $115M (-$68.1M)

42% less call options, than puts

Call options by funds: $59K | Put options by funds: $102K

Holders
90
Holders Change
-4
Holders Change %
-4.26%
% of All Funds
1.43%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
40
Reduced
20
Closed
18
Calls
$59K
Puts
$102K
Net Calls
-$43K
Net Calls Change
+$6K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$1.57M
2
BlackRock
BlackRock
New York
+$1.54M
3
WP
Woodline Partners
California
+$1M
4
Morgan Stanley
Morgan Stanley
New York
+$833K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$758K

Top Sellers

Rank Fund Capital Flow
1
MS
Maven Securities
Jersey
-$2.5M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.36M
3
MIM
Monashee Investment Management
Massachusetts
-$1.27M
4
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$1.04M
5
GCM
Ghisallo Capital Management
Massachusetts
-$994K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$20.8M +$477K +6,997 +2%
AG
2
Artal Group
Luxembourg
$14.2M – – –
WA
3
Wasatch Advisors
Utah
$13.6M -$961K -14,097 -5%
Alkeon Capital Management
4
Alkeon Capital Management
New York
$9.9M – – –
GC
5
GMT Capital
Georgia
$9.05M +$318K +4,661 +3%
BlackRock
6
BlackRock
New York
$8.27M +$1.54M +22,664 +16%
Vanguard Group
7
Vanguard Group
Pennsylvania
$5.92M +$177K +2,592 +2%
WP
8
Woodline Partners
California
$4.44M +$1M +14,724 +20%
RG
9
Redmile Group
California
$4.1M – – –
Geode Capital Management
10
Geode Capital Management
Massachusetts
$2.54M +$758K +11,123 +28%
AIG
11
American International Group
New York
$2.48M +$15.5K +228 +0.5%
State Street
12
State Street
Massachusetts
$2.35M +$468K +6,871 +17%
JP Morgan Chase
13
JP Morgan Chase
New York
$2.27M -$109K -1,598 -3%
Massachusetts Financial Services
14
Massachusetts Financial Services
Massachusetts
$1.79M -$534K -7,837 -18%
Millennium Management
15
Millennium Management
New York
$1.6M +$1.57M +22,986 +246%
Wellington Management Group
16
Wellington Management Group
Massachusetts
$1.28M +$593K +8,703 +50%
Morgan Stanley
17
Morgan Stanley
New York
$1.19M +$833K +12,228 +103%
Northern Trust
18
Northern Trust
Illinois
$1.02M -$117K -1,711 -8%
Charles Schwab
19
Charles Schwab
California
$887K +$243K +3,561 +25%
Renaissance Technologies
20
Renaissance Technologies
New York
$718K +$78.9K +1,158 +9%
Marshall Wace
21
Marshall Wace
United Kingdom
$698K – – –
Goldman Sachs
22
Goldman Sachs
New York
$660K -$46.2K -678 -5%
UOC
23
UBS O'Connor
Illinois
$495K +$178K +2,609 +35%
Bank of New York Mellon
24
Bank of New York Mellon
New York
$361K +$39.3K +576 +9%
N
25
Nuveen
North Carolina
$351K -$3.13K -46 -0.6%
1
2 3 4 5

KLRS Hedge Fund Activity: Q3 2023 in Review

90 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q3 2023, worth a combined $115M — down 37% from $184M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of KLRS and 14 opened new positions — a net loss of 4 holders — while 20 trimmed existing stakes and 40 added.

The largest buyer was Millennium Management, adding an estimated $1.57M. The largest seller was Maven Securities, exiting entirely with an estimated $2.5M sold.

  • 90 institutional investors held Kalaris Therapeutics (KLRS) as of Q3 2023, down from 94 in Q2 2023.
  • Funds reported $115M of Kalaris Therapeutics stock for Q3 2023, down 37% quarter-over-quarter.
  • 14 funds opened new Kalaris Therapeutics positions in Q3 2023 and 18 closed out, a net change of -4 holders.
  • The largest Kalaris Therapeutics buyer in Q3 2023 was Millennium Management, an estimated $1.57M added.
  • The largest Kalaris Therapeutics seller in Q3 2023 was Maven Securities, an estimated $2.5M sold.

Based on aggregated 13F filings for Q3 2023.